← feed

Is NCT02524782 results overdue?

Yes — results are overdue. Primary completion was 2017-04-14; the FDAAA-801 reporting deadline (2018-04-14) passed 2990 days ago and no results are posted on ClinicalTrials.gov.

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

NCT IDNCT02524782 ↗
SponsorMedImmune LLC (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-04-14 (ACTUAL)
Reporting deadline2018-04-14 (completion + 365d)
Days overdue2990
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 69b7ea111cc28c9f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02524782. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →